BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27765904)

  • 1. Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.
    Zhen YF; Li ST; Zhu YR; Wang XD; Zhou XZ; Zhu LQ
    Oncotarget; 2016 Nov; 7(48):79417-79427. PubMed ID: 27765904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
    Wu L; Zhang J; Wu H; Han E
    Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting DNA-PK
    Mamo T; Mladek AC; Shogren KL; Gustafson C; Gupta SK; Riester SM; Maran A; Galindo M; van Wijnen AJ; Sarkaria JN; Yaszemski MJ
    Biochem Biophys Res Commun; 2017 Apr; 486(2):307-313. PubMed ID: 28300555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.
    Cheng L; Liu YY; Lu PH; Peng Y; Yuan Q; Gu XS; Jin Y; Chen MB; Bai XM
    Oncotarget; 2017 Apr; 8(17):28385-28394. PubMed ID: 28415690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine.
    Hu H; He Y; Wang Y; Chen W; Hu B; Gu Y
    Biochem Biophys Res Commun; 2017 Jan; 483(1):725-731. PubMed ID: 27988337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.
    Zhu YR; Zhou XZ; Zhu LQ; Yao C; Fang JF; Zhou F; Deng XW; Zhang YQ
    Oncotarget; 2016 Aug; 7(31):49527-49538. PubMed ID: 27385099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
    Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
    Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repair of radiation damage of U2OS osteosarcoma cells is related to DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activity.
    Tang X; Yuan F; Guo K
    Mol Cell Biochem; 2014 May; 390(1-2):51-9. PubMed ID: 24390088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.
    Chen MB; Zhou ZT; Yang L; Wei MX; Tang M; Ruan TY; Xu JY; Zhou XZ; Chen G; Lu PH
    Oncotarget; 2016 Mar; 7(13):17047-59. PubMed ID: 26933997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Potentials of DNA-PKcs, Ku80, and ATM in enhancing radiosensitivity of cervical carcinoma cells].
    Zhuang L; Yu SY; Huang XY; Cao Y; Xiong HH
    Ai Zheng; 2007 Jul; 26(7):724-9. PubMed ID: 17626748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival.
    Tu Y; Ji C; Yang B; Yang Z; Gu H; Lu CC; Wang R; Su ZL; Chen B; Sun WL; Xia JP; Bi ZG; He L
    Mol Cancer; 2013 Dec; 12(1):172. PubMed ID: 24365180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2α expression and cell proliferation.
    Zheng B; Mao JH; Li XQ; Qian L; Zhu H; Gu DH; Pan XD
    Sci Rep; 2016 Jul; 6():29415. PubMed ID: 27412013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.
    Long XH; Zhong ZH; Peng AF; Zhu LB; Wang H; Zhang GM; Liu ZL
    Mol Med Rep; 2014 Dec; 10(6):2967-72. PubMed ID: 25310590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
    Zhang Y; Duan G; Feng S
    Biochem Biophys Res Commun; 2015 Apr; 459(3):367-73. PubMed ID: 25727016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.
    Dolman ME; van der Ploeg I; Koster J; Bate-Eya LT; Versteeg R; Caron HN; Molenaar JJ
    PLoS One; 2015; 10(12):e0145744. PubMed ID: 26716839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63.
    Li X; Tian J; Bo Q; Li K; Wang H; Liu T; Li J
    Tumour Biol; 2015 Dec; 36(12):9365-72. PubMed ID: 26108997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salinomycin simultaneously induces apoptosis and autophagy through generation of reactive oxygen species in osteosarcoma U2OS cells.
    Kim SH; Choi YJ; Kim KY; Yu SN; Seo YK; Chun SS; Noh KT; Suh JT; Ahn SC
    Biochem Biophys Res Commun; 2016 Apr; 473(2):607-13. PubMed ID: 27033598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salinomycin activates AMP-activated protein kinase-dependent autophagy in cultured osteoblastoma cells: a negative regulator against cell apoptosis.
    Zhu LQ; Zhen YF; Zhang Y; Guo ZX; Dai J; Wang XD
    PLoS One; 2013; 8(12):e84175. PubMed ID: 24358342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair.
    Gustafsson AS; Abramenkovs A; Stenerlöw B
    Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.
    Tang QL; Zhao ZQ; Li JC; Liang Y; Yin JQ; Zou CY; Xie XB; Zeng YX; Shen JN; Kang T; Wang J
    Cancer Lett; 2011 Dec; 311(1):113-21. PubMed ID: 21835542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.